RET targeted treatment of medullary thyroid carcinoma / 国际肿瘤学杂志

ABSTRACT

Medullary thyroid carcinoma(MTC), which includes sporadic type and hereditary type, is a kind of malignant tumor in thyroid parafollicular cells. MTC is the common clinical character of the multiple en-docrine neoplasia type 2 (MEN 2), including MEN 2A and MEN 2B, and familial medullary thyroid carcinoma(FMTC). The RET gene encodes a receptor tyrosine kinase, its mutations and polymorphisms can induce acti-vation of the BET tyrosine kinase domain via different signal pathways resulting the genesis of MTC. RET has been used as a target for MTC molecular therapy. However, a clinically useful therapeutic option for treating pa-tients with RET-associated cancer is still not available.